We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AGI | AGI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.25 |
| Top Posts |
|---|
Posted at 16/5/2012 14:44 by wexboy AGI Therapeutics - Final Part IV: |
Posted at 01/5/2012 00:19 by wexboy AGI Therapeutics Part III - let's talk about Expected Return & fighting home bias w/ currency target allocations: |
Posted at 24/4/2012 05:09 by wexboy AGI Therapeutics: Risk Arb - An In-Depth Look at a Takeover Investment - Part II: |
Posted at 09/1/2012 07:03 by topinfo Offer for AGI Therapeutics plcAlert TIDMAGI RNS Number : 1836V AGI Therapeutics plc 09 January 2012 For immediate release Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction 09 January 2012 PRE-CONDITIONAL RECOMMENDED CASH OFFER BY ARAVIS THERAPEUTICS LIMITED FOR AGI THERAPEUTICS PLC Summary -- The boards of Aravis Therapeutics Limited ("Aravis") and AGI Therapeutics plc ("AGI") are pleased to announce that they have reached agreement on the terms of a recommended cash offer by Aravis for the entire issued and to be issued share capital of AGI. -- AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat un-met medical needs, including conditions which qualify for orphan drug status. -- Under the terms of the Offer, AGI Shareholders will be entitled to receive US$0.1171 in cash for each AGI Share they own. -- AGI Shareholders will be able to elect to receive their entire cash consideration pursuant to the Offer either in US Dollars or Euro. The Euro cash amount payable will be determined based on the prevailing US$/EUR exchange rate either on the day the Offer becomes or is declared wholly unconditional or if valid acceptances are received after that date then on the day their cash consideration is converted into Euro. -- The Offer values the entire issued and to be issued share capital of AGI at approximately US$8.4 million (EUR6.6 million). -- Based on the closing US$/EUR exchange rate of 1.2776 on 06 January 2012, being the latest practicable date prior to the date of this announcement, the Offer values each AGI Share at EUR0.0917. This represents: -- a premium of approximately 67 per cent. to the Closing Price of EUR0.055 per AGI Share on 06 January 2012, being the last Business Day prior to the date of this announcement; -- a premium of approximately 130 per cent. to the average daily Closing Price per AGI Share for the three months up to the last Business Day prior to the date of this announcement, being EUR0.040; -- a premium of approximately 137 per cent. to the average daily Closing Price per AGI Share for the six months up to the last Business Day prior to the date of this announcement, being EUR0.039. -- The making of the Offer is conditional upon satisfaction of the pre-condition set out in Appendix III to this announcement. The pre-condition requires Aravis to receive by 12 noon on the date of this announcement irrevocable undertakings in a form satisfactory to Aravis from AGI Directors, and the AGI Investors to accept (or procure the acceptance of) the Offer in respect of 31,359,118 AGI Shares and, to the extent exercised, 4,200,000 "in the money" AGI Share Options, in aggregate representing approximately 49.6 per cent. of the entire issued and to be issued share capital of AGI at the date of this announcement. -- The Board of AGI, which has been so advised by Davy Corporate Finance, considers the terms of the Offer to be fair and reasonable. In providing its advice, Davy has taken into account the commercial assessments of the Board of AGI. -- Accordingly, the Board of AGI unanimously recommends that AGI Shareholders accept the Offer. Commenting on the Offer, Ronan Lambe, Non-Executive Chairman of AGI, said: "AGI is pleased to announce the Offer, which has been unanimously recommended by our Board of Directors. We believe the Offer represents an attractive premium relative to our recent share price trading history and when the Offer is considered alongside other alternatives the Offer represents the best outcome for Shareholders". This summary should be read in conjunction with the full text of the following announcement and appendices. The Offer will be subject to the conditions and further terms set out in Appendix I of this announcement, which will also be set out in the Offer Document and the Form of Acceptance. Appendix II contains the bases of calculation and sources of certain information contained in this announcement. Appendix III sets out the pre-condition to the making of the Offer. Appendix IV sets out definitions of certain terms used in this announcement (including in this summary). Davy Corporate Finance is acting as financial adviser to AGI. Beauchamps Solicitors are acting as legal adviser to AGI. Goodbody Corporate Finance is acting as financial adviser to the Aravis Group. A&L Goodbody is acting as Irish legal adviser and Burke, Warren, MacKay & Serritella, P.C is acting as US legal adviser to the Aravis Group. Enquiries: |
Posted at 09/11/2011 17:08 by kamose AGI Therapeutics plc ('AGI')Holding in Company AGI was notified on the 9th November 2011 that Paul Johnson has increased his shareholding to 2,720,615 shares representing 4.04% of AGI's Issued share capital. |
Posted at 04/11/2011 11:48 by moreforus ok which one of you is Paul??Holding(s) in Company TIDMAGI RNS Number : 5266R AGI Therapeutics plc 04 November 2011 AGI Therapeutics plc ('AGI') Holding in Company AGI was notified on 2(nd) November 2011 that Paul Johnson has increased his shareholding to 2,050,615 shares representing 3.04% of AGI's Issued share capital. Contact Information AGI Therapeutics David G. Kelly, Chief Financial Officer Tel: +353 1 449 3254 This information is provided by RNS The company news service from the London Stock Exchange END HOLUSSARASAARAA |
Posted at 07/10/2011 09:41 by fairdeal2008 well a decent rns on the lead programme would make this interesting as certasinly tightly coiled. From the interims:-- The first six months of 2011 were dominated by the pre-clinical evaluation of AGI-350,, a novel presentation of an existing marketed drug which AGI is developing to treat a significant unmet medical need in the critical care setting. -- AGI has completed preliminary development and in-vitro evaluation of a form and formulation of AGI-350 which is specifically designed to provide effective and efficient delivery of the drug to the lung. -- AGI entered into a technology access agreement with Aerogen Ltd. to provide specialized aerosol technology for the administration and delivery of AGI-350 to ventilated patients in the Intensive Care Unit (ICU) setting. This proprietary technology is being customized for use with AGI-350 in the target patient population and prototypes have been developed for pre-clinical evaluation. -- Furthermore, AGI has initiated a pre-clinical programme for AGI-350 which is ongoing. A model of the target condition has been developed and is being employed to characterise AGI-350 and generate key proof of concept data to inform subsequent clinical development. Once this phase of evaluation is completed in H2 2011, AGI will consider the next steps for this programme, which may involve advancing the product into human trials. -------------------- ps H2 ends 31 Dec so we are very close to news on agi-350 now. imho dyor |
Posted at 29/6/2011 08:38 by christianf12 This is from share tip website www.watshot.com 8 days ago (similar to AGI, they tipped MOS at 4p last year):AGI Therapeutics (AGI) - Trading below net cash Drug developer AGI Therapeutics is currently valued at £2.6 million, well below its cash pile of $10 million (as at 31st December 2010). The firm concentrates its efforts in the area of specialty indications with unmet medical needs, with particular focus on treatments for conditions which qualify for Orphan Drug status (i.e. those drugs that are applicable for significant competitive advantages such as exclusivity periods, mainly due to the critical nature of the disease). The firm recently identified a promising new lead product candidate, AGI-350, (described as "a novel presentation of an existing marketed drug which AGI will develop to treat a significant unmet medical need in the critical care setting") for which a programme of pre-clinical testing has commenced. "AGI-350 is specifically formulated to allow effective and efficient delivery of the drug directly to the lung to treat a life-threatening, lung-related, condition. There are currently no formulations of the drug available for inhaled delivery, and AGI believes that AGI-350 will represent the first such approved use of the drug to treat the target critical care population." There are currently major changes underway in the pharmaceutical industry, notably the reduction in large pharma R&D budgets, that will see small biotech come under increasing scrutiny, both from the majors and the market in general. Tucking away a few of these might be a very rewarding punt over the next couple of years or so. The cash burn is around $3 million a year so plenty of space for interest to build here. |
Posted at 29/3/2011 09:01 by fairdeal2008 I just think it is a classic 'under-radar' opportunity.The results statement from last week included £6million plus cash at bank at 31/12/10, with ongoing low cash burn. It also noted a new lead candidate for the drug programme as follows (quoting from rns: New Lead Development Candidate AGI-350 is a novel presentation of an existing marketed drug which AGI will develop to treat a significant unmet medical need in the critical care setting. AGI-350 is specifically formulated to allow effective and efficient delivery of the drug directly to the lung to treat a life-threatening, lung-related, condition. There are currently no formulations of the drug available for inhaled delivery, and AGI believes that AGI-350 will represent the first such approved use of the drug to treat the target critical care population. AGI expects that AGI-350 will qualify for Orphan Drug status, which, if granted, should provide seven to ten years exclusivity post approval in key markets. AGI anticipates the pre-clinical development phase, which includes testing in an established disease model, will be completed during H2, 2011. Depending on the outcome of these studies, AGI plans to prepare and file an Investigational New Drug (IND) application with a view to commencing a proof of concept clinical trial in patients during H1, 2012. For commercial and intellectual property reasons, the drug name and target indication cannot be disclosed at this time. ------ On top of all that the Finance Director bought £25,000 of stock on Friday. So we have cash twice the market cap, a new lead candidate that could be offered Orphan drug status and an FD throwing a serious lump of cash into the business. At some point I believe this will rerate significantly. imho |
Posted at 23/3/2011 09:27 by topinfo Great RNS!!TIDMAGI RNS Number : 4650D AGI Therapeutics plc 23 March 2011 AGI Therapeutics, plc Preliminary financial results for the year ended 31 December 2010 AGI announces new lead programme and provides business update Enters into development agreement with Aerogen Dublin, Ireland, 23 March 2011 - AGI Therapeutics, plc ("AGI" or the "Company"), a specialty pharmaceutical company, today reports preliminary financial results for the year ended 31 December 2010, and provides a business update to shareholders. Financial highlights -- Cash and short-term deposits at 31 December 2010 of $10.0 million, (2009: $12.0 million) -- Research and Development (R&D) spend of $1.4 million (2009: $8.3 million) -- Reduced net loss of $3.6 million (2009: $10.6 million) -- Loss per ordinary share of 5.3 cents (2009: 15.8 cents) Operational Summary In 2010, AGI announced that it would re-focus its research and development efforts in the area of specialty indications with unmet medical needs, with particular focus on treatments for conditions which qualify for Orphan Drug status. During the year the Company evaluated a number of potential products, both internal and external, which met this criteria. The R&D costs of $1.4 million incurred in 2010 reflect these efforts, which included conducting a number of feasibility studies on potential new pipeline candidates to validate and support further development. Today, as a result of these efforts, AGI is pleased to announce that it has identified a promising new lead product candidate, AGI-350, for which a programme of pre-clinical testing has commenced. New Lead Development Candidate AGI-350 is a novel presentation of an existing marketed drug which AGI will develop to treat a significant unmet medical need in the critical care setting. AGI-350 is specifically formulated to allow effective and efficient delivery of the drug directly to the lung to treat a life-threatening, lung-related, condition. There are currently no formulations of the drug available for inhaled delivery, and AGI believes that AGI-350 will represent the first such approved use of the drug to treat the target critical care population. AGI expects that AGI-350 will qualify for Orphan Drug status, which, if granted, should provide seven to ten years exclusivity post approval in key markets. AGI anticipates the pre-clinical development phase, which includes testing in an established disease model, will be completed during H2, 2011. Depending on the outcome of these studies, AGI plans to prepare and file an Investigational New Drug (IND) application with a view to commencing a proof of concept clinical trial in patients during H1, 2012. For commercial and intellectual property reasons, the drug name and target indication cannot be disclosed at this time. Collaboration with Aerogen AGI is also pleased to announce today that it has entered into a development agreement with Aerogen Limited, to provide specialised aerosol technology for the administration and delivery of AGI-350 to ventilated patients in the Intensive Care Unit (ICU) setting. This collaboration will involve the customisation of Aerogen's proprietary technology for use with AGI-350 in the target patient population. Commenting on the results, Dr. John Devane, CEO of AGI, said: "During 2010 we completed a process of rigorous technical and commercial due diligence and identified a new lead programme and direction for the Company. We are also pleased to enter into a collaboration with Aerogen in support of AGI-350 and we look forward to providing further updates on the progress of this programme during the course of this year". Contact Information: AGI Therapeutics plc. Tel: +353 1 449 3254 David Kelly, Chief Financial Officer Davy Tel: +353 1 614 8761 John Frain For further information: www.agitherapeutics. Notes to Editors: |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
